Gold bars to be exempt from tariffs, White House clarifies
Annovis Bio Inc. (NYSE:ANVS), a clinical-stage pharmaceutical company, has announced the completion of patient enrollment for a key Phase II/III trial of its leading compound buntanetap. The drug is being studied for its potential to treat mild to moderate Alzheimer's Disease (AD), a condition affecting memory and cognition.
The enrollment process, which began in March, successfully registered over 350 participants across the United States. The study is placebo-controlled and dose-ranging, designed to evaluate the effectiveness of buntanetap in addressing the symptoms associated with AD.
Earlier reports from the Data Safety Monitoring Board (DSMB) have been promising. On October 12, 2023, the DSMB's interim report showed positive efficacy outcomes for buntanetap. Subsequently, on October 30, 2023, after a thorough review of safety data, the DSMB recommended the trial to continue without any modifications.
The trial's progress is a significant milestone for Annovis Bio, which focuses on developing transformative therapies for neurodegenerative diseases, including both Alzheimer's and Parkinson's diseases. The company and the medical community are eagerly awaiting the final results of the study, which are expected by the end of March 2024. These findings will provide critical insights into buntanetap's capacity to improve the lives of individuals suffering from memory loss and dementia associated with Alzheimer's Disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.